LAB Standard BioTools Inc.
Healthcare$1.03-0.96%ClosedMarket Cap: $402.1M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.71
P/S
4.66
EV/EBITDA
-2.30
DCF Value
$-1.46
FCF Yield
-23.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.3%
Operating Margin
-91.0%
Net Margin
-109.1%
ROE
-20.8%
ROA
-14.7%
ROIC
-7.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $21.1M | 53.5% | $-9.4M | $-45.2M | $— | — |
| Q4 null | $23.8M | 43.0% | $-21.9M | $19.3M | $— | — |
| FY null | $85.3M | 49.9% | $-93.3M | $-74.9M | $— | — |
| Q3 null | $19.6M | 48.5% | $-23.5M | $-34.7M | $— | — |
| Q2 null | $21.8M | 48.8% | $-23.7M | $-33.5M | $— | — |
| Q1 null | $20.2M | 54.6% | $-24.2M | $-26.0M | $— | — |
| Q4 null | $46.7M | 46.9% | $-32.8M | $-34.1M | $— | — |
| FY null | $174.4M | 48.3% | $-175.2M | $-138.9M | $— | — |
| Q3 null | $45.0M | 51.7% | $-31.7M | $-26.9M | $— | — |
| Q2 null | $22.5M | 46.1% | $-30.3M | $-45.7M | $— | — |
| Q1 null | $45.5M | 53.1% | $-60.2M | $-32.2M | $— | — |
| Q4 2023 | $28.2M | 47.4% | $-21.4M | $-19.8M | $-0.25 | — |